Related Experiment Video
Updated: Apr 26, 2026

A Chemical Screening Procedure for Glucocorticoid Signaling with a Zebrafish Larva Luciferase Reporter System
Published on: September 10, 2013
The in vitro interference of synthetic progestogens with carp steroidogenic enzymes
Denise Fernandes1, Sílvia Pujol1, Jaume Aceña1
1Environmental Chemistry Department, IDAEA-CSIC, Jordi Girona 18, 08034 Barcelona, Spain.
Abstract:
Synthetic progestogens represent a class of pharmaceuticals widely used in oral contraceptives and in hormone replacement therapies. They reach the aquatic environment through wastewater effluents; however, environmental concentrations and effects on non-target organisms are poorly known. Given the important role of progestogens regulating fish spawning processes, this study aimed at assessing the in vitro interference of four currently used progestogens-drospirenone (DRO), levonorgestrel (LNG), norethindrone (NOR) and cyproterone acetate (CPA) - with key enzymatic activities involved in the synthesis of active steroids in carp (Cyprinus carpio). The enzymatic pathways investigated were (a) CYP17 (C17,20-lyase) and CYP11β involved in the synthesis of androgens, (b) CYP19 that catalyses the aromatization of androgens to estrogens, and (c) 20β-hydroxysteroid dehydrogenase (20β-HSD) responsible for the synthesis of maturation-inducing hormones. All tested progestogens significantly inhibited the synthesis of androgens: DRO (IC50: 3.8 μM) was the strongest inhibitor of CYP17 followed by CPA (IC50s: 183 μM). Moreover, NOR (IC50: 0.4 μM), DRO (IC50: 1.8 μM) and CPA (IC50s: 87 μM) inhibited CYP11β. An inhibition by NOR of ovarian CYP19 activity, and by DRO and CPA of 20β-HSD was also observed, but at rather high concentrations (500 μM). Overall, this study highlights the potential of synthetic progestogens, and particularly DRO and NOR, to interfere with the biosynthesis of androgens in carp gonads.
More Related Videos
Related Concept Videos
Pharmacokinetics: Drug–Drug Interactions
Inhibitors of Viral Protein Synthesis
GPCRs Regulate Adenylyl Cylase Activity
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...

